To review the pharmacology and clinical data for febuxostat in the treatment of gout and hyperuricemia.
Data Sources:
Articles on febuxostat published in English between 1966 and November 2006 were identified through a MEDLINE search using the key words febuxostat, TEI-6720, TMX-67, gout, and hyperuricemia. Additional articles were identified through search of the publications' reference lists. Abstracts from the 2005 proceedings of the American College of Rheumatology, American College of Clinical Pharmacology, and American Society for Clinical Pharmacology and Therapeutics were also searched for febuxostat studies.
Study Selection and Data Extraction:
All published febuxostat trials in humans were selected for this review. Clinical, pharmacokinetic, and pharmacodynamic data were evaluated.
Data Synthesis:
Febuxostat is a non-purine, selective inhibitor of xanthine oxidase that has demonstrated efficacy in lowering serum uric acid levels in patients with hyperuricemia associated with gout. Compared with allopurinol 300 mg/day, febuxostat 80 or 120 mg/day was more effective in lowering serum uric acid levels to less than 6 mg/dL. Febuxostat appears to be safe, with the majority of treatment-related adverse events reported being transient and mild-to-moderate in severity. However, abnormal elevation of liver enzyme levels has been reported with its use. There have been no documented major drug interactions with febuxostat.
Conclusions:
Febuxostat is a novel, non-purine xanthine oxidase inhibitor undergoing review by the FDA. It represents a potential advancement in the treatment of hyperuricemia associated with gout.
Get full access to this article
View all access options for this article.
References
1.
SchlesingerN.Management of acute and chronic gouty arthritis. Present state-of-the-art. Drugs2004; 64: 2399–416.
2.
TerkeltaubRA. Gout. N Engl J Med2003; 349: 1647–55.
3.
KramerHMCurhanG. The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis2002; 40: 37–42.
4.
RottKTAgudeloCA. Gout. JAMA2003; 289: 2857–60.
5.
van DoornumSRyanPF. Clinical manifestations of gout and their management. Med J Aust2000; 172: 493–7.
6.
ScottJT. Gout. Ann Rheum Dis1983; 42 (suppl): 16S–8S.
7.
HawkinsDWRahnDW. Gout and hyperuricemia. In: DipiroJTTalbertRLYeeGCMatzkeGRWellsBGPoseyLM, eds. Pharmacotherapy. A pathophysiologic approach. 4th ed.Stamford, CT: Appelton & Lange, 1999: 1460–5.
8.
SnaithML. ABC of rheumatology. Gout, hyperuricemia, and crystal arthritis. BMJ1995; 310: 521–4.
9.
McGillNW. Gout and other crystal naturopathies. Med J Aust1997; 166: 33–8.
10.
PerkinsPJonesAC. Gout. Ann Rheum Dis1999; 58: 611–6.
11.
WallaceSLRobinsonHMasiATDeckerJLMcCartyDJYuTF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum1977; 20: 895–900.
12.
CampionEWGlynnRJDeLabryLO. Asymptomatic hyperuricemia: Risk and consequences in the Normative Aging Study. Am J Med1987; 82: 421–6.
13.
McCartyDJ. Gout without hyperuricemia. JAMA1994; 271: 302–3.
14.
ShojiAYamanakaHKamataniN. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum2004; 51: 321–5.
15.
StuartRAGowPJBellamyNCampbellJGrigorR. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis. N Z Med J1991; 104: 116–8.
16.
SchumacherHR. Crystal-induced arthritis: An overview. Am J Med1996; 100 (suppl 2A): 46S–52S.
17.
RosenthalAKRyanLM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am1995; 21: 151–61.
18.
FerrazMB. An evidence based appraisal of the management of nontophaceous interval gout. J Rheumatol1995; 22: 1618–9.
19.
FamAG. Should patients with interval gout be treated with urate lowering drugs?J Rheumatol1995; 22: 1621–3.
20.
BardinT. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine2004; 71: 481–5.
21.
FriesJF. Advances in management of rheumatic disease. 1965 to 1985. Arch Intern Med1989; 149: 1002–11.
22.
OkamotoKEgerBTNishinoTKondoSPaiEFNishinoT.An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem2003; 278: 1848–55.
23.
OsadaYTsuchimotoMFukushimaH, Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol1993; 241: 183–8.
24.
KomoriyaKOsadaYHasegawaM, Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol1993; 250: 455–60.
25.
BeckerMAKisickiJKhosravanR, Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids2004; 23: 1111–6.
26.
KomoriyaKHoshideSTakedaK, Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids2004; 23: 1119–22.
27.
TakanoYHase-AokiKHoriuchiH, Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci2005; 76: 1835–47.
28.
KhosravanRGrabowskiBAMayerMDWuJTJoseph-RidgeNVernilletL. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol2006; 46: 88–102.
29.
MayerMDKhosravanRVernilletLWuJTJoseph-RidgeNMulfordDJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther2005; 12: 22–34.
30.
KhosravanRGrabowskiBWuJTJoseph-RidgeNVernilletL. Effect of food or antacid on febuxostat pharmacokinetics and pharmacodynamics in healthy subjects (abstract). Clin Pharmacol Ther2005; 77: P50.
31.
KhosravanRKukulkaMWuJTJoseph-RidgeNVernilletL. Effects of age and gender on febuxostat pharmacokinetics, pharmacodynamics, and safety in healthy subjects (abstract). Clin Pharmacol Ther2005; 77: P50.
32.
HoshideSTakahashiYIshikawaT, PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids2004; 23: 1117–8.
33.
KhosravanRMayerMDWuJTJoseph-RidgeNVernilletL.Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state (abstract). Presented at: American College of Rheumatology Annual Scientific Meeting, San Diego, November 14, 2005.
34.
KhosravanRWuJTJoseph-RidgeNVernilletL. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. Clin Pharmacol2006; 46: 855–66.
35.
GrabowskiBAKhosravanRWuJTLademacherCVernilletL.Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat (abstract). Presented at: American College of Rheumatology Annual Scientific Meeting, San Diego, November 14, 2005.
36.
KhosravanRWuJTLademacherCGrabowskiBAVernilletL. Effect of febuxostat on pharmacokinetics and pharmacodynamics of warfarin (abstract). J Clin Pharmacol2005; 45: 1084.
37.
BeckerMASchumacherHRJrWortmannRL, Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose–response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum2005; 52: 916–23.
38.
YamanakaHTogashiRHakodaM, Optimal range of serum urate concentrations to minimize risk of gouty attacks during antihyperuricemic treatment. Adv Exp Med Biol1998; 431: 13–8.
39.
BorstadGCBryantLRAbelMPScroggieDAHarrisMDAllowayJA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol2004; 31: 2429–32.
40.
BeckerMASchumacherHRJrWortmannRL, Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med2005; 353: 2450–61.
41.
LustbergME. Febuxostat versus allopurinol for gout (letter). N Engl J Med2006; 354: 1532–3; author reply 1532–3.
42.
MorelandLW. Febuxostat—treatment for hyperuricemia and gout (editorial)?N Engl J Med2005; 353: 2505–7.
43.
SchumacherHRBeckerMAWortmannRL, Febuxostat vs allopurinol and placebo in subjects with hyperuricemia (abstract). Presented at: American College of Rheumatology Annual Scientific Meeting, San Diego, November 16, 2005.
